PF-07321332 hinders the SARS-CoV-2-3CL protease activity, an enzyme required by the virus for its replication. Credit: NIAID / Flickr.

The US Government has signed an agreement with Pfizer to procure ten million courses of the company’s Covid-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), for $5.29bn, on obtaining the US Food and Drug Administration (FDA) authorisation.

The experimental antiviral PF-07321332 hinders the SARS-CoV-2-3CL protease activity, an enzyme required by the virus for its replication.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is given along with a low ritonavir dose to delay PF-07321332’s metabolism, or breakdown aiding it to be active in the body for a longer time at greater concentrations to fight the virus.

Pfizer sought Emergency Use Authorization (EUA) from the FDA for Paxlovid to treat Covid-19 patients with mild-to-moderate symptoms.

According to the deal, Pfizer intends to deliver the ten million courses of the pill to the US Government starting later this year and ending next year.

In addition to this deal, the company signed advance purchase agreements with various nations and has begun bilateral outreach to nearly 100 countries globally.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pfizer chairman and CEO Albert Bourla said: “We were thrilled with the recent results of our Phase II/III interim analysis, which showed overwhelming efficacy of Paxlovid in reducing the risk of hospitalisation among high-risk patients treated within three days of symptom onset by almost 90% and with no deaths, and are pleased the US government recognises this potential.

“It is encouraging to see a growing understanding of the valuable role that oral investigational therapies may play in combatting Covid-19 and we look forward to continuing discussions with governments around the world to help ensure broad access for people everywhere.”

Interim analysis data from the company’s Phase II/III clinical trial showed that Paxlovid lowered Covid-19-linked mortality and hospitalisation.